Cognitive Decline and Antihypertensive Use: New Data

TOPLINE:
Deprescribing antihypertensive medications is associated with a 12% lower likelihood of cognitive decline in older nursing home residents, a new study suggests. The association was strongest among those with dementia.
METHODOLOGY:
The cohort study included 12,644 long-term care residents (mean age, 77.7 years; 97% men; 17.5% Black) with stays of at least 12 weeks from 2006 to 2019.
Residents who experienced either a reduction in the total number of antihypertensive medications or a sustained 30% decrease in dosage for at least 2 weeks were classified as deprescribing users (n = 1290). Those with no medication changes were considered stable users (n = 11,354).
The primary outcome was cognitive impairment assessed using the four-point Cognitive Function Scale (CFS), with the score proportional to the severity of impairment.
The median follow-up duration was 23 weeks for the deprescribing users and 21 weeks for the stable users.
TAKEAWAY:
Deprescribing antihypertensives was associated with a 12% lower likelihood of progressing to a worse CFS per 12-week period (odds ratio [OR], 0.88; 95% CI, 0.78-0.99) compared with stable users.
Among residents with dementia, deprescribing was associated with a 16% reduced likelihood of cognitive decline per 12-week period (OR, 0.84; 95% CI, 0.72-0.98).
At the end of follow-up, 12% of residents had a higher CFS score and 7.7% had a lower CFS score.
In the intention-to-treat analysis, the association between deprescribing antihypertensive medications and reduced cognitive decline remained consistent (OR, 0.94; 95% CI, 0.90-0.98).
IN PRACTICE:
“This work highlights the need for patient-centered approaches to deprescribing, ensuring that medication regimens for older adults are optimized to preserve cognitive function and minimize potential harms,” the study authors wrote.
SOURCE:
The study was led by Bocheng Jing, MS, Department of Medicine, University of California, San Francisco. It was published online on September 23 in JAMA Internal Medicine.
LIMITATIONS:
The study population included predominantly men and White individuals, limiting the generalizability of the results to women and other racial and ethnic groups. The findings may not be applicable to patients with heart failure owing to their noninclusion. The specificity of dementia diagnosis was limited, as this study combined various forms of dementia, making it challenging to differentiate the impacts among subgroups.
DISCLOSURES:
This study was supported by the US National Institute on Aging. Two authors reported receiving grants, honoraria, consulting fees, or royalties from various sources. Details are provided in the original article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
 
Send comments and news tips to [email protected].